特发性肺纤维化治疗新药—尼达尼布

Idiopathic pulmonary fibrosis new drug—nintedanib

目的评价特发性肺纤维化治疗药物尼达尼布的作用机制、药效学、安全药理学、临床前毒理学、药动学和临床疗效。方法根据已报道的关于尼达尼布药理毒理学相关文献10篇,按照临床前药效学、安全药理学、临床前毒理学、药动学、临床研究等五个方面进行了总结和分类综述。结果尼达尼布是迄今为止FDA批准的首个用于IPF治疗的药物,能够通过与VEGFR、PDGFR、FGFR酪氨酸激酶的ATP结合位点特异性结合,有效缓解肺纤维化进程。结论尼达尼布可有效治疗特发性肺纤维化。

Objective To investigate nintedanib＇s mechanism,pharmacology,safety pharmacology,pre-clinical toxicology,pharmacokinetics and clinical pharmacodynamics. Methods According to the 10 reference papers about pharmacological toxicology of nintedanib,we summarized the preclinical pharmacodynamic,safety pharmacology,clinical toxicology,pharmacokinetics and clinical studies of it. Results Nintedanib is the first drug that approvaled by FDA as a potential treatment for idiopathic pulmonary fibrosis. It can slowdisease progression in patients with IPF through binding competitively to the adenosine triphosphate binding pocket of VEGFR,PDGFR,FGFR tyrosine kinase receptors. Conclusions Nintedanib is effective for the treatment of IPF.